Can MALDI-HRMS Make Drug Checking Faster Without Losing Quantitative Value?
Drug-checking programs face a difficult analytical tradeoff. A method must be broad enough to detect unexpected substances, quantitative enough to communicate concentration, and fast enough to deliver information while it still matters. A 2020 study evaluated whether MALDI high-resolution mass spectrometry could meet those competing demands.
What is different about MALDI-HRMS?
Matrix-assisted laser desorption/ionization high-resolution mass spectrometry (MALDI-HRMS) can analyze prepared spots without the chromatographic separation used in conventional liquid- or gas-chromatography workflows. Removing that separation step can shorten analysis, but it raises questions about selectivity, low-concentration compounds, and matrix effects.
The researchers paired high-resolution mass measurement with an online spectral library for untargeted searching. That combination was intended to identify known drugs, emerging designer drugs, adulterants, and contaminants without limiting the analysis to a narrow preset panel.
What did the investigators test?
Sixty-seven real drug-checking samples were analyzed. The method detected ten designer drugs along with classical substances—especially cocaine and MDMA—and multiple adulterants or contaminants. Results were compared with routine LC-MS and GC-MS analyses of the same samples.
For quantitative validation, the team developed assays for cocaine and MDMA. Trueness ranged from -2.7% to 14.4%, while repeatability and intermediate precision ranged from 3.9% to 13.7%. The investigators found that averaging more than 100 spectra was necessary to bring relative variability below 10%.
How close were the quantitative results?
The MALDI measurements agreed with the routine LC-MS/MS results within a ±20% tolerance window. The reported calibration relationships were strong, and the MALDI workflow required about three minutes per sample, compared with a 14-minute LC injection. Overall, the authors described the complete analytical procedure as up to six times faster.
The study also observed different MDMA concentration ranges by product form: pills contained lower MDMA percentages than powders in this sample set. That finding is descriptive of the submitted samples, not a universal rule for every market or time period.
What does “faster” not mean?
High throughput does not eliminate method validation. The paper shows that acquisition settings, internal standards, calibration, and the number of spectra averaged all affect performance. Nor does the absence of chromatography become irrelevant. The authors noted that it may be detrimental when low-concentration analytes must be identified in complex matrices.
Drug-checking samples are comparatively concentrated and can be diluted or concentrated during preparation. A method that performs well for seized powder or tablet material is not automatically validated for blood, urine, hair, or tissue.
Why this matters to forensic review
Analytical speed is valuable only when identity, uncertainty, calibration, and limitations remain transparent. A defensible report should state whether the result was presumptive or confirmatory, whether quantitation was validated for the analyte, what library supported identification, and how the method handled mixtures or isomers.
This study supports MALDI-HRMS as a promising high-throughput drug-checking platform. It does not support treating every rapid mass-spectrometric result as equivalent to a fully validated casework method.
Scientific source
Joye T et al. “High-Throughput Qualitative and Quantitative Drug Checking by MALDI HRMS.” Frontiers in Chemistry (2020). PubMed PMID 33195006; DOI 10.3389/fchem.2020.00695.
